Insider Selling: Chinook Therapeutics, Inc. (NASDAQ:KDNY) Insider Sells 5,000 Shares of Stock

Chinook Therapeutics, Inc. (NASDAQ:KDNYGet Rating) insider Andrew James King sold 5,000 shares of Chinook Therapeutics stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the insider now directly owns 5,897 shares of the company’s stock, valued at approximately $117,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew James King also recently made the following trade(s):

  • On Monday, July 11th, Andrew James King sold 5,000 shares of Chinook Therapeutics stock. The stock was sold at an average price of $18.09, for a total transaction of $90,450.00.

Chinook Therapeutics Stock Up 0.3 %

KDNY opened at $20.44 on Friday. Chinook Therapeutics, Inc. has a 1-year low of $10.48 and a 1-year high of $21.11. The company has a fifty day moving average price of $17.97 and a two-hundred day moving average price of $15.38.

Chinook Therapeutics (NASDAQ:KDNYGet Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.14. The company had revenue of $2.70 million during the quarter. Chinook Therapeutics had a negative net margin of 180.48% and a negative return on equity of 23.24%. On average, equities analysts expect that Chinook Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Institutional Investors Weigh In On Chinook Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KDNY. Russell Investments Group Ltd. increased its position in shares of Chinook Therapeutics by 16.0% during the fourth quarter. Russell Investments Group Ltd. now owns 17,849 shares of the company’s stock worth $291,000 after acquiring an additional 2,458 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Chinook Therapeutics during the fourth quarter worth about $194,000. New York State Common Retirement Fund boosted its holdings in Chinook Therapeutics by 31.8% during the fourth quarter. New York State Common Retirement Fund now owns 25,842 shares of the company’s stock worth $421,000 after purchasing an additional 6,240 shares during the last quarter. Monashee Investment Management LLC purchased a new position in Chinook Therapeutics during the fourth quarter worth about $1,549,000. Finally, Northern Trust Corp boosted its holdings in Chinook Therapeutics by 14.6% during the fourth quarter. Northern Trust Corp now owns 348,177 shares of the company’s stock worth $5,679,000 after purchasing an additional 44,339 shares during the last quarter. 84.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Chinook Therapeutics in a research note on Monday, June 27th. They issued a “buy” rating and a $30.00 price target for the company. SVB Leerink lifted their price target on shares of Chinook Therapeutics from $38.00 to $44.00 and gave the company an “outperform” rating in a research note on Monday, May 23rd.

About Chinook Therapeutics

(Get Rating)

Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

Further Reading

Insider Buying and Selling by Quarter for Chinook Therapeutics (NASDAQ:KDNY)

Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.